Abstract: FR-PO171
Monocyte as a Marker of Renal Damage in Patients with Glomerular Hyperfiltration and Early CKD
Session Information
- CKD: Epidemiology, Risk Factors, Prevention - II
October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Oh, Sewon, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea (the Republic of)
- Lee, Junyong, Korea universtiy Anam hospital, Seoul, Korea (the Republic of)
- Yang, Jihyun, Korea universtiy Anam hospital, Seoul, Korea (the Republic of)
- Kim, Myung-Gyu, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea (the Republic of)
- Jo, Sang-Kyung, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea (the Republic of)
Background
Experimental studies have shown that monocyte/macrophages play an important role in progression of chronic kidney disease (CKD). Recent epidemiologic study also suggests a significant association between higher monocyte count and risk of incident CKD in humans. Glomerular hyperfiltration (GH) is known as an early marker of progressive CKD in diverse clinical conditions. However, not all patients with GH progressed to CKD and monocyte may be associated with renal injuries caused by GH. The purpose of this study is to examine whether higher monocyte count is associated with GH and progressive kidney disease.
Methods
A longitudinal observational cohort study was performed using data from regular health checkup examinations in tertiary hospital during 2004-2017. We analyzed 56,258 adults at initial examination and selected 16,695 adults who had initial estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m2 with at least two tests of eGFR in follow-up analysis. Monocyte count was categorized into sex-specific quartiles. GH was defined as the upper 2.5 percentile of eGFR in the total population.
Results
The monocyte count showed a U-shaped association with eGFR. The monocyte count was significantly higher in participants with eGFR ≥ 120, 60-74, 45-59, 30-44, and <30 ml/min/1.73m2 compared with those with eGFR 90-104 ml/min/1.73m2 at initial examination (N=56,258, P≤0.025). The highest quartile of monocyte count was independently associated with GH in multivariate analysis compared with the lowest quartile (OR, 1.278; 95% CI, 1.070-1.525). In participants without GH, the highest quartile of monocyte count was associated with the higher risk of ≥ 25% eGFR decline (RR, 1.859; 95% CI, 1.254-2.755) and the development of proteinuria (RR, 1.377; 95% CI, 1.135-1.671) compared with lowest quartile. In participants with GH, the highest quartile was also associated with increased risk for the development of proteinuria (RR, 5.833; 95% CI, 1.196-28.453), but was not associated with ≥ 25% eGFR decline.
Conclusion
Higher monocyte count is associated with progressive CKD. In addition, monocyte count could be a marker to identify patients at risk for progression of kidney disease in GH.